Actively Recruiting

Phase 3
Age: 18Years - 100Years
All Genders
NCT05126277

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Led by Novartis Pharmaceuticals · Updated on 2026-03-18

462

Participants Needed

188

Research Sites

447 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This trial will evaluate efficacy, safety, and tolerability of subcutaneous (s.c.) ianalumab given every 4 weeks (q4w) or every 12 weeks (q12w) compared to placebo, in combination with SoC, in adult participants with active LN

CONDITIONS

Official Title

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Who Can Participate

Age: 18Years - 100Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 years or older at screening
  • Weigh at least 35 kg
  • Confirmed diagnosis of systemic lupus erythematosus (SLE) per EULAR/ACR criteria
  • Positive anti-nuclear antibody (ANA) test with titer ≥ 1:80
  • Active lupus nephritis with kidney biopsy within 6 months showing ISN/RPS class III, IV with or without class V, or pure class V membranous
  • Urine protein to creatinine ratio (UPCR) ≥ 1.0 g/g on 24-hour urine collection
  • Estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m2; if eGFR < 30, biopsy must show ≤ 50% glomeruli sclerosis
  • Newly diagnosed or pre-treated lupus nephritis patients on or willing to start standard induction therapy with mycophenolic acid (MPA)
  • Induction therapy including high-dose corticosteroids and MPA started before or on day of randomization
  • Stable anti-malarial treatment recommended unless contraindicated
  • Switch from azathioprine to MPA before randomization if applicable
  • Received at least one dose of pulse methylprednisolone intravenous therapy within 60 days before randomization or started on oral prednisone if unable to receive pulse therapy
  • Able to communicate and comply with study requirements
Not Eligible

You will not qualify if you...

  • Severe renal impairment defined as oliguria (<400 mL urine/24 hrs), end-stage renal disease requiring dialysis or transplantation
  • Kidney biopsy showing >50% glomeruli sclerosis
  • Use of other investigational drugs within 5 half-lives or 30 days before enrollment
  • Prior use of ianalumab or recent B cell depleting therapies within 36 weeks
  • Treatment with certain immunosuppressants or biologics within 12 weeks before randomization
  • Discontinuation of imidazole derivatives before starting MPA
  • More than 3000 mg cumulative intravenous pulse methylprednisolone within 12 weeks prior to randomization
  • History of major organ or bone marrow transplant or planned transplantation
  • Hemoglobin <8.0 g/dL or <7.0 g/dL if due to active hemolytic anemia
  • Platelet count <25,000/µL or absolute neutrophil count <800/µL
  • Active infections requiring intravenous or intramuscular treatment or recurrent significant infections
  • Known intolerance or allergy to MPA, corticosteroids, or study drug components
  • Receipt of live or attenuated vaccine within 4 weeks prior to randomization
  • History of immunodeficiency including positive HIV test
  • History of malignancy within past 5 years except certain skin or cervical cancers
  • Medical, psychiatric, or surgical conditions that could jeopardize participation
  • Chronic hepatitis B or C infection or positive hepatitis B surface antigen
  • Active tuberculosis infection
  • Pregnant or nursing women
  • Women of child-bearing potential not using effective contraception during and for 6 months after treatment
  • Sexually active men not agreeing to use barrier protection with women of child-bearing potential

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 188 locations

1

University Of Alabama

Birmingham, Alabama, United States, 35294

Actively Recruiting

2

Advanced Medical Research

La Palma, California, United States, 90623

Actively Recruiting

3

Wallace Rheumatic Study Center

Los Angeles, California, United States, 90048

Withdrawn

4

University of California LA

Los Angeles, California, United States, 90095

Actively Recruiting

5

University of California Irvine

Orange, California, United States, 92868

Actively Recruiting

6

School Of Medicine

Sacramento, California, United States, 95817

Actively Recruiting

7

University of California San Diego

San Diego, California, United States, 92037

Actively Recruiting

8

Kaiser Permanente

San Diego, California, United States, 92111

Actively Recruiting

9

Mayo Clinic Jacksonville

Jacksonville, Florida, United States, 32224

Actively Recruiting

10

University Of Miami

Miami, Florida, United States, 33136

Actively Recruiting

11

Emory University School of Medicine

Atlanta, Georgia, United States, 30303

Actively Recruiting

12

Fides Clinical Research

Atlanta, Georgia, United States, 30342

Actively Recruiting

13

Parris and Associates Rheumatology

Lawrenceville, Georgia, United States, 30044

Actively Recruiting

14

University of Kansas Hospital

Kansas City, Kansas, United States, 66160

Withdrawn

15

Accurate Clinical Research

Lake Charles, Louisiana, United States, 70601

Actively Recruiting

16

UMC New Orleans

New Orleans, Louisiana, United States, 70112

Actively Recruiting

17

Wayne State University

Detroit, Michigan, United States, 48201

Actively Recruiting

18

Univ of Nevada School of Med

Las Vegas, Nevada, United States, 89102

Actively Recruiting

19

Sahni Rheumatology and Therapy

West Long Branch, New Jersey, United States, 07764

Withdrawn

20

VA NM Healthcare System

Albuquerque, New Mexico, United States, 87108

Actively Recruiting

21

NY Nephrology

Clifton Park, New York, United States, 12065

Actively Recruiting

22

Hospital for Special Surgery

New York, New York, United States, 10021

Actively Recruiting

23

Northwell Health

New York, New York, United States, 10028

Actively Recruiting

24

Circuit Clinical

Orchard Park, New York, United States, 14127

Actively Recruiting

25

James J Peters VA Medical Center

The Bronx, New York, United States, 10468

Actively Recruiting

26

Brookview Hills Research Assoc

Winston-Salem, North Carolina, United States, 27103

Withdrawn

27

University Of Cincinnati

Cincinnati, Ohio, United States, 45267

Active, Not Recruiting

28

Univ of Pennsylvania Medical Center

Philadelphia, Pennsylvania, United States, 19104

Active, Not Recruiting

29

Arthritis and Rheumatology Ins

Allen, Texas, United States, 75013

Actively Recruiting

30

Precision Comprehensive Research

Colleyville, Texas, United States, 76034

Active, Not Recruiting

31

Liberty Research Center

Dallas, Texas, United States, 75230

Actively Recruiting

32

Univof Texas Southwestern Med Cntr

Dallas, Texas, United States, 75235

Actively Recruiting

33

University of Texas Medical Branch

Galveston, Texas, United States, 77555-0144

Withdrawn

34

Uni of Texas Health Science Center

San Antonio, Texas, United States, 78229

Actively Recruiting

35

Baylor Scott and White Research

Temple, Texas, United States, 76502

Actively Recruiting

36

Northern Assoc of Northern VA

Fairfax, Virginia, United States, 22033

Actively Recruiting

37

Uni Wisconsin School Med Pub Health

Madison, Wisconsin, United States, 53792

Actively Recruiting

38

Novartis Investigative Site

CABA, Buenos Aires, Argentina, C1056ABI

Actively Recruiting

39

Novartis Investigative Site

Caba, Buenos Aires, Argentina, C1119ACN

Withdrawn

40

Novartis Investigative Site

La Plata, Buenos Aires, Argentina, B1900AWT

Actively Recruiting

41

Novartis Investigative Site

Caba, Argentina, C1015ABO

Actively Recruiting

42

Novartis Investigative Site

CABA, Argentina, C1426ABP

Actively Recruiting

43

Novartis Investigative Site

San Miguel de Tucumán, Argentina, 4000

Actively Recruiting

44

Novartis Investigative Site

Vitória, Espírito Santo, Brazil, 29055 450

Active, Not Recruiting

45

Novartis Investigative Site

Salvador, Estado de Bahia, Brazil, 40150 150

Actively Recruiting

46

Novartis Investigative Site

São Luís, Maranhão, Brazil, 65020-600

Withdrawn

47

Novartis Investigative Site

Belo Horizonte, Minas Gerais, Brazil, 30150-221

Active, Not Recruiting

48

Novartis Investigative Site

Juiz de Fora, Minas Gerais, Brazil, 36010 570

Active, Not Recruiting

49

Novartis Investigative Site

Curitiba, Paraná, Brazil, 80440-020

Withdrawn

50

Novartis Investigative Site

Recife, Pernambuco, Brazil, 50740-900

Active, Not Recruiting

51

Novartis Investigative Site

Porto Alegre, Rio Grande do Sul, Brazil, 90035-003

Active, Not Recruiting

52

Novartis Investigative Site

Porto Alegre, Rio Grande do Sul, Brazil, 90035-074

Active, Not Recruiting

53

Novartis Investigative Site

Santo André, São Paulo, Brazil, 09090-790

Active, Not Recruiting

54

Novartis Investigative Site

Salvador, Brazil, 40323-010

Active, Not Recruiting

55

Novartis Investigative Site

Calgary, Alberta, Canada, T2N 4Z6

Actively Recruiting

56

Novartis Investigative Site

Vancouver, British Columbia, Canada, V5Z 1L7

Active, Not Recruiting

57

Novartis Investigative Site

Winnipeg, Manitoba, Canada, R3A 1R9

Active, Not Recruiting

58

Novartis Investigative Site

Etobicoke, Ontario, Canada, M9W 6V1

Actively Recruiting

59

Novartis Investigative Site

London, Ontario, Canada, N6A 5W9

Actively Recruiting

60

Novartis Investigative Site

Toronto, Ontario, Canada, M5T 2S8

Actively Recruiting

61

Novartis Investigative Site

Montreal, Quebec, Canada, H1T 2M4

Actively Recruiting

62

Novartis Investigative Site

Sherbrooke, Quebec, Canada, J1G 2E8

Actively Recruiting

63

Novartis Investigative Site

Santiago, RM, Chile, 7500922

Active, Not Recruiting

64

Novartis Investigative Site

Temuco, Chile, 4781151

Active, Not Recruiting

65

Novartis Investigative Site

Hefei, Anhui, China, 230022

Withdrawn

66

Novartis Investigative Site

Guangzhou, Guangdong, China, 510000

Active, Not Recruiting

67

Novartis Investigative Site

Guangzhou, Guangdong, China, 510080

Active, Not Recruiting

68

Novartis Investigative Site

Guangzhou, Guangdong, China, 510120

Active, Not Recruiting

69

Novartis Investigative Site

Shantou, Guangdong, China, 515000

Active, Not Recruiting

70

Novartis Investigative Site

Shenzhen, Guangdong, China, 518020

Withdrawn

71

Novartis Investigative Site

Shenzhen, Guangdong, China, 518037

Active, Not Recruiting

72

Novartis Investigative Site

Liuzhou, Guangxi, China, 545005

Active, Not Recruiting

73

Novartis Investigative Site

Haikou, Hainan, China, 570311

Active, Not Recruiting

74

Novartis Investigative Site

Wuhan, Hubei, China, 430022

Active, Not Recruiting

75

Novartis Investigative Site

Wuhan, Hubei, China, 430060

Active, Not Recruiting

76

Novartis Investigative Site

Changsha, Hunan, China, 410008

Active, Not Recruiting

77

Novartis Investigative Site

Nanjing, Jiangsu, China, 210029

Active, Not Recruiting

78

Novartis Investigative Site

Nanchang, Jiangxi, China, 330006

Active, Not Recruiting

79

Novartis Investigative Site

Changchun, Jilin, China, 130041

Active, Not Recruiting

80

Novartis Investigative Site

Shenyang, Liaoning, China, 110004

Active, Not Recruiting

81

Novartis Investigative Site

Binzhou, Shandong, China, 256603

Active, Not Recruiting

82

Novartis Investigative Site

Linyi, Shandong, China, 276000

Active, Not Recruiting

83

Novartis Investigative Site

Xian, Shanxi, China, 710004

Active, Not Recruiting

84

Novartis Investigative Site

Chengdu, Sichuan, China, 610041

Active, Not Recruiting

85

Novartis Investigative Site

Ningbo, Zhejiang, China, 315016

Active, Not Recruiting

86

Novartis Investigative Site

Beijing, China, 100034

Active, Not Recruiting

87

Novartis Investigative Site

Chongqing, China, 400038

Active, Not Recruiting

88

Novartis Investigative Site

Guangzhou, China, 510080

Active, Not Recruiting

89

Novartis Investigative Site

Guangzhou, China, 510280

Active, Not Recruiting

90

Novartis Investigative Site

Shanghai, China, 200040

Active, Not Recruiting

91

Novartis Investigative Site

Shanghai, China, 200080

Active, Not Recruiting

92

Novartis Investigative Site

Shanghai, China, 200127

Completed

93

Novartis Investigative Site

Medellín, Antioquia, Colombia, 050001

Actively Recruiting

94

Novartis Investigative Site

Barranquilla, Atlántico, Colombia, 080020

Actively Recruiting

95

Novartis Investigative Site

Bogota, Cundinamarca, Colombia, 110111

Actively Recruiting

96

Novartis Investigative Site

Olomouc, Czechia, 779 00

Active, Not Recruiting

97

Novartis Investigative Site

Prague, Czechia, 128 00

Active, Not Recruiting

98

Novartis Investigative Site

Tallinn, Estonia, 10117

Actively Recruiting

99

Novartis Investigative Site

Tallinn, Estonia, 10138

Actively Recruiting

100

Novartis Investigative Site

Angers, France, 49933

Withdrawn

101

Novartis Investigative Site

Besançon, France, 25030

Active, Not Recruiting

102

Novartis Investigative Site

Bordeaux, France, 33076

Actively Recruiting

103

Novartis Investigative Site

Grenoble, France, 38043

Actively Recruiting

104

Novartis Investigative Site

Lyon, France, 69003

Actively Recruiting

105

Novartis Investigative Site

Marseille, France, 13005

Actively Recruiting

106

Novartis Investigative Site

Poitiers, France, 86021

Actively Recruiting

107

Novartis Investigative Site

Toulouse, France, 31054

Actively Recruiting

108

Novartis Investigative Site

Vandœuvre-lès-Nancy, France, 54511

Actively Recruiting

109

Novartis Investigative Site

Regensburg, Bavaria, Germany, 93053

Withdrawn

110

Novartis Investigative Site

Aachen, Germany, 52074

Actively Recruiting

111

Novartis Investigative Site

Bochum, Germany, 44791

Actively Recruiting

112

Novartis Investigative Site

Münster, Germany, 48149

Actively Recruiting

113

Novartis Investigative Site

Guatemala City, Guatemala, 01010

Actively Recruiting

114

Novartis Investigative Site

Guatemala City, Guatemala, 01011

Active, Not Recruiting

115

Novartis Investigative Site

Quetzaltenango, Guatemala, 9001

Active, Not Recruiting

116

Novartis Investigative Site

Kwun Tong, Kowloon, Hong Kong

Actively Recruiting

117

Novartis Investigative Site

Tuenmen, Hong Kong, 999077

Actively Recruiting

118

Novartis Investigative Site

Debrecen, Hajdu Bihar Megye, Hungary, 4032

Actively Recruiting

119

Novartis Investigative Site

Budapest, Hungary, H-1032

Actively Recruiting

120

Novartis Investigative Site

Budapest, Hungary, H-1097

Actively Recruiting

121

Novartis Investigative Site

Kaposvár, Hungary, 7400

Actively Recruiting

122

Novartis Investigative Site

Bangalore, Karnataka, India, 560 079

Active, Not Recruiting

123

Novartis Investigative Site

Secunderabad, Telangana, India, 500003

Actively Recruiting

124

Novartis Investigative Site

Secunderabad, Telangana, India, 500003

Active, Not Recruiting

125

Novartis Investigative Site

Lucknow, Uttar Pradesh, India, 226014

Actively Recruiting

126

Novartis Investigative Site

Chandigarh, India, 160 012

Actively Recruiting

127

Novartis Investigative Site

Cagliari, CA, Italy, 09134

Withdrawn

128

Novartis Investigative Site

Foggia, FG, Italy, 71122

Actively Recruiting

129

Novartis Investigative Site

Florence, FI, Italy, 50134

Actively Recruiting

130

Novartis Investigative Site

Milan, MI, Italy, 20132

Actively Recruiting

131

Novartis Investigative Site

Pavia, PV, Italy, 27100

Actively Recruiting

132

Novartis Investigative Site

Roma, RM, Italy, 00168

Actively Recruiting

133

Novartis Investigative Site

Torino, TO, Italy, 10154

Actively Recruiting

134

Novartis Investigative Site

Udine, UD, Italy, 33100

Actively Recruiting

135

Novartis Investigative Site

Naples, Italy, 80131

Withdrawn

136

Novartis Investigative Site

Kaunas, LTU, Lithuania, LT 50161

Actively Recruiting

137

Novartis Investigative Site

Vilnius, Lithuania, LT-08406

Actively Recruiting

138

Novartis Investigative Site

Kuala Lumpur, Kuala Lumpur, Malaysia, 50586

Actively Recruiting

139

Novartis Investigative Site

Sibu, Sarawak, Malaysia, 96000

Actively Recruiting

140

Novartis Investigative Site

Kuala Terengganu, Terengganu, Malaysia, 20400

Actively Recruiting

141

Novartis Investigative Site

León, Guanajuato, Mexico, 37160

Actively Recruiting

142

Novartis Investigative Site

Monterrey, Nuevo León, Mexico, 64440

Actively Recruiting

143

Novartis Investigative Site

Oaxaca City, Mexico, 68020

Actively Recruiting

144

Novartis Investigative Site

Querétaro, Mexico, 76000

Withdrawn

145

Novartis Investigative Site

Querétaro, Mexico, 76070

Actively Recruiting

146

Novartis Investigative Site

Cluj-Napoca, Cluj, Romania, 400006

Actively Recruiting

147

Novartis Investigative Site

Oradea, Jud Bihor, Romania, 410619

Actively Recruiting

148

Novartis Investigative Site

Timișoara, Timiș County, Romania, 300723

Actively Recruiting

149

Novartis Investigative Site

Râmnicu Vâlcea, Vâlcea County, Romania, 240672

Withdrawn

150

Novartis Investigative Site

Bucharest, Romania, 011172

Actively Recruiting

151

Novartis Investigative Site

Bucharest, Romania, 022328

Actively Recruiting

152

Novartis Investigative Site

Singapore, Singapore, 169608

Actively Recruiting

153

Novartis Investigative Site

Singapore, Singapore, S308433

Actively Recruiting

154

Novartis Investigative Site

Bundang Gu, Gyeonggi-do, South Korea, 13620

Actively Recruiting

155

Novartis Investigative Site

Suwon, Gyeonggi-do, South Korea, 16499

Actively Recruiting

156

Novartis Investigative Site

Daejeon, Korea, South Korea, 35015

Withdrawn

157

Novartis Investigative Site

Busan, South Korea, 49201

Actively Recruiting

158

Novartis Investigative Site

Daegu, South Korea, 705 718

Withdrawn

159

Novartis Investigative Site

Gwangju, South Korea, 61469

Actively Recruiting

160

Novartis Investigative Site

Seoul, South Korea, 03722

Actively Recruiting

161

Novartis Investigative Site

Seoul, South Korea, 04763

Actively Recruiting

162

Novartis Investigative Site

Seoul, South Korea, 05030

Withdrawn

163

Novartis Investigative Site

Seoul, South Korea, 05505

Actively Recruiting

164

Novartis Investigative Site

Seoul, South Korea, 06591

Actively Recruiting

165

Novartis Investigative Site

Santiago Compostela, A Coruna, Spain, 15706

Actively Recruiting

166

Novartis Investigative Site

Barcelona, Catalonia, Spain, 08003

Actively Recruiting

167

Novartis Investigative Site

El Palmar, Murcia, Spain, 30120

Withdrawn

168

Novartis Investigative Site

Pamplona, Navarre, Spain, 31008

Actively Recruiting

169

Novartis Investigative Site

Vigo, Pontevedra, Spain, 36214

Actively Recruiting

170

Novartis Investigative Site

San Cristóbal de La Laguna, Santa Cruz De Tenerife, Spain, 38320

Actively Recruiting

171

Novartis Investigative Site

Valencia, Valencia, Spain, 46017

Actively Recruiting

172

Novartis Investigative Site

Barcelona, Spain, 08035

Actively Recruiting

173

Novartis Investigative Site

Madrid, Spain, 28040

Actively Recruiting

174

Novartis Investigative Site

Madrid, Spain, 28041

Actively Recruiting

175

Novartis Investigative Site

Madrid, Spain, 280796

Actively Recruiting

176

Novartis Investigative Site

Kaohsiung City, Taiwan, 83301

Actively Recruiting

177

Novartis Investigative Site

Taichung, Taiwan, 40447

Actively Recruiting

178

Novartis Investigative Site

Taichung, Taiwan, 407219

Actively Recruiting

179

Novartis Investigative Site

Taipei, Taiwan, 11217

Actively Recruiting

180

Novartis Investigative Site

Songkhla, Hat Yai, Thailand, 90110

Actively Recruiting

181

Novartis Investigative Site

Bangkok, Thailand, 10330

Actively Recruiting

182

Novartis Investigative Site

Bangkok, Thailand, 10400

Actively Recruiting

183

Novartis Investigative Site

Bangkok, Thailand, 10700

Actively Recruiting

184

Novartis Investigative Site

Chiang Mai, Thailand, 50200

Actively Recruiting

185

Novartis Investigative Site

Bradford, West Yorkshire, United Kingdom, BD9 6RJ

Actively Recruiting

186

Novartis Investigative Site

London, United Kingdom, SE1 9RT

Actively Recruiting

187

Novartis Investigative Site

Hanoi, Vietnam, 100000

Active, Not Recruiting

188

Novartis Investigative Site

Ho Chi Minh City, Vietnam, 700000

Active, Not Recruiting

Loading map...

Research Team

N

Novartis Pharmaceuticals

CONTACT

N

Novartis Pharmaceuticals

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | DecenTrialz